Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge

J Thromb Thrombolysis. 2018 Jan;45(1):51-55. doi: 10.1007/s11239-017-1578-x.

Abstract

The objective of this project was to compare the time from initiation of oral anticoagulation to hospital discharge between warfarin and direct oral anticoagulants (DOACs) for the treatment of acute venous thromboembolism (VTE). This retrospective observational study was done at a single VA medical center. A total of 107 patients were included, with 42 patients (39%) in the DOAC group, which included rivaroxaban, dabigatran, and apixaban, and 65 patients (61%) in the warfarin group. Variables collected through chart review included comorbid conditions, time from initiation of oral anticoagulation to discharge, emergency department (ED) visits and readmission within 30 or 90 days, and bleeding events. The DOAC group had a shorter time to discharge compared to the warfarin group (28 vs. 114 h, p < 0.001). There were similar 30 and 90-day hospital readmission rates and/or ED visits for DOACs (23.8 and 33.3%) compared to warfarin (18.5 and 30.8%), including those related to bleeding of any severity (11.9% for DOACs vs. 9.2% for warfarin; p = 0.75). There was one major bleeding event in the DOAC group and two in the warfarin group. The use of DOACs for the treatment of acute VTE in hospitalized patients was associated with shorter time to hospital discharge when compared to warfarin.

Keywords: Anticoagulation; DOAC; Length of stay; Venous thromboembolism; Warfarin.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage*
  • Anticoagulants / therapeutic use
  • Dabigatran / therapeutic use
  • Female
  • Hemorrhage / chemically induced
  • Humans
  • Length of Stay*
  • Male
  • Middle Aged
  • Patient Readmission
  • Pyrazoles / therapeutic use
  • Pyridones / therapeutic use
  • Retrospective Studies
  • Rivaroxaban / therapeutic use
  • Venous Thromboembolism / drug therapy*
  • Warfarin / administration & dosage*

Substances

  • Anticoagulants
  • Pyrazoles
  • Pyridones
  • apixaban
  • Warfarin
  • Rivaroxaban
  • Dabigatran